Parse Biosciences, a leader in accessible and scalable single-cell sequencing solutions, has announced the creation of the world’s largest single-cell dataset to date, comprising 100 million cells. This milestone was achieved in just one month using Parse Biosciences’ GigaLab platform, in collaboration with Vevo Therapeutics to accelerate their AI-driven drug discovery initiatives.
Parse Biosciences, a leader in scalable single-cell sequencing solutions, has announced the creation of the world’s largest single-cell dataset to date—Tahoe-100—comprising 100 million cells, 60,000 conditions, and 1,200 drug treatments across 50 different tumor models. This dataset was generated in collaboration with Vevo Therapeutics to support their AI-driven drug discovery efforts. In addition to the Tahoe-100 dataset, the Parse GigaLab is involved in various large-scale projects, including additional perturbation screens, AI generative models, and population study atlases.
Johnny Yu, Chief Scientific Officer and Co-Founder of Vevo, expressed the significance of this achievement: “This dataset is a major milestone for the Vevo team and the Mosaic platform. By leveraging the Parse GigaLab, we can now produce the essential data to power AI-driven drug discovery with unprecedented speed and scale, allowing us to accelerate the discovery of new treatments.”
Using Parse’s Evercode™ technology, the GigaLab can generate massive single-cell datasets at remarkable speed. The Tahoe-100 dataset, for instance, had the wet lab portion of the workflow completed in just one month. This rapid process was enabled by the UG 100™ high-throughput sequencing platform in collaboration with Ultima Genomics, which provides ultra-low-cost, high-quality sequencing data.
Alex Rosenberg, CEO and co-founder of Parse Biosciences, commented, “This project showcases GigaLab’s ability to deliver immense speed, quality, and scalability. We are excited to bring the power of GigaLab to Vevo and other biopharma partners to enable breakthrough discoveries and drive drug development forward.”
About Parse Biosciences
Parse Biosciences is a global life sciences company focused on accelerating human health and scientific research. The company enables single-cell sequencing at an unparalleled scale, with applications across cancer treatment, stem cell therapy, liver disease, brain development, and more. Parse Biosciences’ technology was developed at the University of Washington by co-founders Alex Rosenberg and Charles Roco. The company has raised over $100 million and is used by more than 2,000 customers worldwide. Their product portfolio includes Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR, Gene Select, and the data analytics platform, Trailmaker™.
About Vevo Therapeutics
Vevo Therapeutics is a biotechnology company dedicated to advancing drug discovery through its in vivo platform and next-gen AI models. The company’s Mosaic platform is the first to scale in vivo data generation with single-cell accuracy, offering insights into disease context and patient diversity early in drug development. Vevo is building the world’s largest in vivo atlas of how drugs interact with patient cells, using AI models to discover new targets and drugs undetectable by other technologies. Based in San Francisco, Vevo Therapeutics is backed by leading investors, including General Catalyst, Wing Venture Capital, Mubadala Capital, and AIX Ventures.
